TOP2B and neuroblastoma: We showed that TOP2B remains overexpressed in neuroblastoma, particularly in younger and neonatal patients and that TOP2B expression is driven higher by MYCN overexpression, explaining the selective activity of CX-5461 against neuroblastoma cells.